<DOC>
	<DOCNO>NCT01392183</DOCNO>
	<brief_summary>The goal clinical research study compare pazopanib temsirolimus treatment advance clear-cell renal cell carcinoma . The safety drug also study . Pazopanib design block growth blood vessel supply nutrient need tumor growth . This may prevent slow growth cancer cell . Temsirolimus design block growth cancer cell , may cause cancer cell die .</brief_summary>
	<brief_title>Pazopanib Versus Temsirolimus Poor-Risk Clear-Cell Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description>Study Groups Study Drug Administration : If find eligible take part study , randomly assign ( flip coin ) 1 2 study group . You equal chance assign either group . - If assign Group 1 , take pazopanib mouth 1 time every day time day empty stomach ( least 1 hour 2 hour meal ) . - If assign Group 2 , receive temsirolimus vein 1 time every week 30-60 minute . About 30 minute receive dose temsirolimus , receive Benadryl ( diphenhydramine ) vein 1-2 minute help low risk side effect . If assign Group 1 , crush tablet repeat missed dos le 12 hour next schedule dose . You give pill diary record take dose . You return diary study doctor study visit . If side effect , tell study doctor right away . If study doctor think best interest , dose may lower . If disease get bad study , option change study group originally assign take study drug . The study drug dose study visit schedule , study doctor discus important detail time change study group . Study Visits : Every 4 week study call study cycle . Every week Cycle 1 ( Group 1 ) , blood pressure check ( either home , clinic , local doctor ) . If check blood pressure home , need write blood pressure blood pressure diary time check bring diary clinic visit . Every 2 week first 2 cycle ( Group 1 ) , blood ( 3 tablespoon ) draw routine test . Every week ( Group 2 ) , blood ( 1 tablespoon ) drawn routine test . Every cycle ( Group 2 ) OR Every cycle ( Group 1 ) : - You physical exam , include measurement weight vital sign . - You ask drug treatment may receive . - You ask side effect may . - Blood ( 3 tablespoon ) collect routine test . On Day 1 Cycle 2 , Day 1 Cycle 4 , every 4 cycle ( Group 1 ) , ECG check heart function . If Group 2 , Day 1 Cycles 2 , 3 , every cycle ( Cycles 5 , 7 , 9 , ) , blood ( 3 tablespoon ) draw routine test . You ask fast ( eat nothing drink water ) least 8 hour blood draw . Every 2 cycle : - You image scan screen . After 1 year treatment , image scan may do every 3 cycle ( Cycles 5 , 8 , 11 , ) . - You fill quality-of-life questionnaire . - Blood ( 2 teaspoon ) drawn test check thyroid function ( Group 1 ) . - Urine collect routine test . Every 4 cycle , ECG ( Group 2 ) . Every 6 cycle , ECHO MUGA scan check heart function . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . End-of-Treatment Follow- : About 30 day stop treatment , clinic visit phone , ask drug treatment may receive side effect may . Long-Term Follow-up : After stop taking study drug , study staff check ask every 3 month . The study staff collect information need either medical record call . If contact phone , call last 5 minute . This investigational study . Pazopanib temsirolimus FDA approve commercially available treatment kidney cancer . It investigational compare 2 drug . Up 90 patient enrol study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Pathologic confirmation metastatic locally advance RCC major clear cell component . 2 . Measurable disease RECIST criterion . 3 . Age &gt; /= 18 year 4 . ECOG performance status 02 Karnofsky Performance Status &gt; /= 60 % 5 . Meets criteria poorrisk define 3 following : ECOG performance status 2 , anemia ( hemoglobin low reference range ) , elevate serum LDH &gt; 1.5x upper limit normal ( ULN ) , hypercalcemia ( correct serum calcium level &gt; upper limit normal ) , time initial RCC diagnosis registration trial &lt; 1 year , &gt; 1 metastatic organ site . 6 . Adequate organ marrow function within 14 day registration define : ) Absolute neutrophil count &gt; /=1,500/µL b ) Platelets &gt; /=100,000/µL c ) Hgb &gt; /= 9.0 g/dL ( transfusion allow ) ) Renal : serum creatinine &lt; /= 1.5 x ULN calculate CrCl &gt; /= 40 cc/min random urine protein : creatinine ratio ( UPC ) &lt; 1 24hr urine protein &lt; 1g e ) Liver : total bilirubin &lt; /= 1.5 mg/dl ; AST ( SGOT ) ALT ( SGPT ) &lt; /= 2.5 x ULN subject without evidence liver metastasis , &lt; /= 5 x ULN subject document liver metastasis f ) INR &lt; /= 1.2 x ULN ; PTT &lt; /= 1.5 x ULN . Therapeutic anticoagulation warfarin allow target INR &lt; /= 3 stable dose warfarin stable dose LMW heparin &gt; 2 week ( 14 day ) time randomization . 7 . Female patient childbearing potential ( postmenopausal least 12 month surgically sterile ) must negative serum urine pregnancy test within 14 day study registration . Pregnancy test must repeat perform &gt; 14 day start study drug . 1 . Prior malignancy , except nonmelanoma skin cancer , situ carcinoma site , cancer patient adequately treated disease free 2 year 2 . Prior targeted therapy ( antiVEGF agent mTOR inhibitor ) include adjuvant therapy , prior chemotherapy mRCC . However , prior immunotherapy ( cytokines vaccine ) allow . 3 . Any experimental drug study ; however , concomitant bone target therapy ( bisphosphonates antiRANK ligand denosumab ) allow . 4 . Uncontrolled brain metastasis infection . Patients brain metastasis treat Gamma Knife ( GK ) whole brain radiation within 24 hour registration . 5 . History stroke within 6 month registration 6 . Clinically significant cardiovascular disease , define myocardial infarction ( unstable angina ) within 6 month registration , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac dysrhythmia refractory medical management . However , treat control stable/not clinically significant cardiovascular disease allow per evaluation cardiologist . 7 . Uncontrolled hypertension ( home blood pressure reading permit ) prior history hypertensive crisis hypertensive encephalopathy ; however , treatment hypertension medication permit . 8 . History uncontrolled hemoptysis ( &gt; /= 1/2 teaspoon bright red blood per episode ) within 1 month prior Day 1 9 . Significant vascular disease include aortic aneurysm , aortic dissection . 10 . Symptomatic peripheral vascular disease 11 . Pregnancy 12 . HIVpositive patient receive combination antiretroviral therapy 13 . Coagulopathy bleed diathesis 14 . Concomitant treatment rifampin , St. John 's wort , cytochrome p450 enzymeinducing antiepileptic drug ( phenytoin , carbamazepine Phenobarbital ) 15 . Major surgery within 28 day prior registration 16 . Core biopsy minor surgical procedure , exclude placement vascular access device within 7 day prior start drug 17 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study registration 18 . Serious nonhealing wound 19 . Baseline QTcB &gt; /= 470 msec .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Kidney cancer</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Poor-Risk Clear-Cell Renal Cell Carcinoma</keyword>
	<keyword>RCC</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Complete response</keyword>
	<keyword>CR</keyword>
	<keyword>Partial Response</keyword>
	<keyword>PR</keyword>
	<keyword>Overall survival</keyword>
	<keyword>OS</keyword>
	<keyword>Time progression</keyword>
	<keyword>TTP</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>GW786034</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>CCI-779</keyword>
	<keyword>Torisel</keyword>
	<keyword>Benadryl</keyword>
	<keyword>Diphenhydramine</keyword>
	<keyword>TemPa</keyword>
</DOC>